#Pharmaceutical-Companies Archive

Editorial & Columns

Insider or an Outsider as a CEO: Insights on Pharmaceutical Industry in India

March 20, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

On the Right Side of Regulations: The USFDA and Indian Pharmaceutical Companies

March 12, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

CSR by Pharmaceutical Companies and Engagement with SHGs, NGOs & Foundations

March 6, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Patent Cliff: Opportunity for Indian Pharmaceutical Companies

February 27, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Product Portfolio of Top Indian Pharmaceutical Companies

January 15, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY24 Review: Attrition and Employee Turnover in Top Indian Pharmaceutical Companies

January 2, 2025 | Dr. Anil Kumar Angrish | No Comments |

More

Business & Economy

Nearly 675 Pharma units in Baddi need ‘tonic’ from Union government to remain alive

December 24, 2024 | Satish Handa | No Comments |

More

Editorial & Columns

Cultivating Intrapreneurship: Lessons from Leading Pharmaceutical Companies

November 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

FY24 Review: Intellectual Capital of Top Indian Pharmaceutical Companies

October 28, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Dividend Policy dynamics of Pharmaceutical Companies in India

October 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

1
2

Contact Us